SPRY

ARS Pharmaceuticals, Inc. (SPRY) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. ARS Pharmaceuticals is a biopharmaceutical company focused on the commercialization of neffy, the first and only FDA and European Commission-approved needle-free intranasal epinephrine product for the emergency treatment of Type I allergic reactions, including anaphylaxis. The company operates as a single segment and relies on third-party manufacturers and international collaboration partners for global distribution outside the United States.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 184% year-over-year, driven by a 125% increase in net product revenue ($17.5M vs. $7.8M) and the recognition of $2.5M in collaboration revenue from the ALK agreement (regulatory milestone and services).
• Expense Expansion: Operating expenses rose 83% to $82.8M. Selling, General, and Administrative (SG&A) expenses increased 76% to $72.2M, primarily due to a $26.4M increase in marketing-related expenses and the ramp-up of the co-promotion agreement with ALK U.S.
• Debt Service: Interest expense of $2.4M was recorded in Q1 2026 related to the $100M Term A Loan secured in September 2025. No interest expense was recorded in Q1 2025.
• Inventory: Total inventory increased slightly to $32.0M. The company holds $5.3M in "zero-cost" inventory (costs previously expensed as R&D prior to FDA approval), which lowers the current Cost of Goods Sold (COGS).

Guidance, Outlook, and Risks

• Commercial Momentum: Approximately 120,000 patients are using neffy in the U.S. as of Q1 2026. The company has achieved ~90% overall commercial coverage. The sales force was expanded to 148 employees in May 2026.
• Global Expansion: neffy has been launched in Japan (Feb 2026) and Australia (Feb 2026). Launches in China and Canada are expected later in 2026.
• Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($201.0M) are sufficient to fund operations for at least the next 12 months. The company has a $250M credit facility with $100M currently drawn.
• Legal & Regulatory Risks:
  • Generic Competition: The company is engaged in patent litigation against Lupin (regarding 1mg and 2mg formulations) and Cipla (regarding 1mg and 2mg formulations) following Paragraph IV certifications. Failure to defend these patents could lead to generic entry.
  • Trade Secret Litigation: AptarGroup filed a suit alleging trade secret misappropriation; the court dismissed the state law claim but allowed federal claims to proceed.
  • FDA Enforcement: The company received untitled letters from the FDA regarding TV advertisements in late 2025 and early 2026, which have since been withdrawn.
• Unusual Items: A significant portion of the ALK Collaboration Agreement upfront payment ($74.2M) is classified as a financing liability due to a repurchase option, rather than immediate revenue.

Investor Verification Checklist

• Verify the status of the patent infringement lawsuits against Lupin and Cipla, as generic entry would materially impact future revenue projections.
• Monitor the gross-to-net yield and rebate rates, as SG&A expenses are heavily weighted toward marketing and payor negotiations.
• Review the ALK Co-Promotion Agreement performance metrics to ensure the partner is meeting ramp-up milestones, which are tied to future bonus payments.
• Assess the timeline for the Phase 2b clinical trial for chronic urticaria, with interim data expected in Q4 2026, as this represents a key growth opportunity beyond anaphylaxis.
• Confirm compliance with the Credit Agreement covenants, specifically the requirement to maintain $25M in unrestricted cash, given the high burn rate.